Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Standard markers in cerebrospinal fluid (CSF), as soluble amyloid beta 1-42 (Abeta1-42) and total tau protein (t-tau), may contribute to dementia subtypes diagnostic accuracy. Yet, their sensitivity to assess the different degree of cognitive deficit is not fully clarified. Our study analyses Abeta1-42 and t-tau CSF levels in different cohorts of Alzheimer's disease (AD) patients, distinguished as early AD (mild cognitively impaired subjects recently converted to AD), mild AD (MMSE or =18), and moderately advanced AD (MMSE<18).

What this study adds

Evidence grade: Low

This study analyzed Aβ1-42 and total tau cerebrospinal fluid levels across groups of Alzheimer's disease patients with different degrees of cognitive impairment. It found these markers were not related to the different degree of cognitive impairment, and it concerns diagnosis rather than treatment, cure, or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Stefani, A., Martorana, A., Bernardini, S., Panella, M., Mercati, F., Orlacchio, A., et al. (2006). CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. Journal of the neurological sciences. https://doi.org/10.1016/j.jns.2006.09.014

Vancouver

Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, et al. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. Journal of the neurological sciences. 2006. doi:10.1016/j.jns.2006.09.014. PMID: 17097109.

BibTeX

@article{stefani2006-17097109,
  author  = {Stefani, A. and Martorana, A. and Bernardini, S. and Panella, M. and Mercati, F. and Orlacchio, A. and Pierantozzi, M.},
  title   = {{CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment}},
  journal = {Journal of the neurological sciences},
  year    = {2006},
  doi     = {10.1016/j.jns.2006.09.014},
  pmid    = {17097109},
  url     = {https://doi.org/10.1016/j.jns.2006.09.014}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This study analyzed Aβ1-42 and total tau cerebrospinal fluid levels across groups of Alzheimer's disease patients with different degrees of cognitive impairment. It found these markers were not related to the different degree of cognitive impairment, and it concerns diagnosis rather than treatment, cure, or prevention.

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 1 of 5; Impact for its field and year 3 of 6; Cited by studies here 3 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 41 of 100.41 of 100 points earned59 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of the neurological sciences)
Journal's citation record 2 / 4 Journal of the Neurological Sciences: journal h-index 233 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2006 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 59 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.7 citations a year over 22 year(s) since 2006
Impact for its field and year 3 / 6 Cited 4.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 10 other studies in this library
Still being cited 1 / 4 Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Mariangela Pierantozzi: h-index 50 (OpenAlex, whole career)
Institution's track record 1 / 3 Sapienza University of Rome: institution h-index 1,145 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 17097109)
Free to read 0 / 2 Behind a paywall — scores zero
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.

Later studies that cite this one

10 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Tau biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →